MedTrace Logo

Seroquel on Glucose Metabolism

NCT00214578 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 572

Last updated 2013-01-04

No results posted yet for this study

Summary

The purpose of this study is to determine whether six months treatment with the antipsychotic medicine Seroquel (quetiapine) may affect the schizophrenic patient's glucose metabolism

Conditions

Interventions

DRUG

Seroquel (quetiapine)

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca CNS Medical Group · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-04-30
Completion
2005-10-31

Countries

  • Bulgaria
  • Czechia
  • Germany
  • Hungary
  • Norway
  • Romania
  • Slovakia
  • South Africa
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00214578 on ClinicalTrials.gov